Key facts
- NED Medical’s last known valuation is $31.0M (Jan 2026).
- It has raised $8.5M across 2 recorded rounds; the latest was Early Stage VC ($8.0M) in Jan 2026.
- Notable investors include Varian Medical Systems.
- NED Medical has filed 2 Form Ds with the SEC since 2023, most recently Feb 2026 ($8.0M sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NED Medical
Funding rounds
2 roundsAbout NED Medical
Developer of radioembolization medical technology designed to improve treatment outcomes for liver cancer. The company's technology helps transform oncology embolisation from a palliative to a curative treatment, reducing debilitating side effects and toxicities, enabling healthcare professionals to provide better treatment to cancer patients.
- Sector
- Healthcare
- HQ
- Norwell, MA, United States
- Founded
- 2022
- Employees
- 5
- Website
- nedmedical.com/
- Ownership
- Privately Held (backing)
NED Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NED Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NED Medical in its N-PORT filings yet. We sweep new filings monthly.